ロード中...
Single, very low rituximab doses in healthy volunteers - a pilot and a randomized trial: implications for dosing and biosimilarity testing
There are no dose-finding trials available for rituximab that could guide dosing in non-malignant diseases. We hypothesized that currently used doses (≥375 mg/m(2)) exceed several hundred-fold the half-maximal effective dose, which is most sensitive for detecting putative differences between biosim...
保存先:
| 出版年: | Sci Rep |
|---|---|
| 主要な著者: | , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Nature Publishing Group UK
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5760686/ https://ncbi.nlm.nih.gov/pubmed/29317666 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-017-17934-6 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|